ERBB2 and cancer: BRCA1 methylation was detected in 76.5% of cancer tissues with positive ER and 64.7% with positive PR; on the other hand, methylation was significantly (p = 0.007) higher among tissues with negative Her2 (68.4%) than those with positive Her2, while 17βHSD-1 promoter methylation was found in cancer tissue specimens in women who had positive ER (66.7%), positive PR (64.1%), and negative Her2 (46.2%).